Meeta Vyas
NANOVIRICIDESAbout Meeta Vyas
Meeta Vyas, SB, MBA, age 66, has served as NanoViricides’ Chief Financial Officer since May 13, 2013. Her background spans GE, McKinsey, Signature Brands, WWF-India, and National Audubon Society, with a track record in turnarounds, operational excellence, and fundraising. Highlights include doubling operating income at GE Appliances’ Range Products (>$1B revenue), leading Signature Brands’ return to profitability, and instituting performance metric processes in non-profit settings. She holds an MBA in Finance from Columbia Business School and an SB in Chemical Engineering from MIT . The company’s filings do not disclose TSR or NNVC revenue/EBITDA performance metrics tied to her tenure or compensation .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| General Electric (GE) | Ran GE Appliances’ Range Products BU | Not disclosed | Doubled operating income in <2 years in a >$1B revenue unit |
| General Electric (GE) | Designed strategy/initiation for IT outsourcing program | Not disclosed | Highly successful IT outsourcing program at GE |
| Signature Brands, Inc. | CEO, Acting COO, Vice Chairman | Not disclosed | Developed/implemented turnaround plan; returned to profitability and growth |
| McKinsey & Company | Management Consultant | Not disclosed | Growth strategies, valuations, post-merger integrations, logistics for public companies |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| World-Wide Fund for Nature – India (WWF-India) | CEO | Not disclosed | Successfully raised unrestricted funding exceeding annual requirements; instituted financial metric processes |
| National Audubon Society (USA) | Vice President | Not disclosed | Raised unrestricted funding and implemented performance processes |
Fixed Compensation
| Year | Base Salary ($) | Bonus ($) | Stock Awards ($) | Option Awards ($) | All Other ($) | Total ($) |
|---|---|---|---|---|---|---|
| 2024 | 129,600 | — | 5,907 | — | — | 133,507 |
| 2025 | 129,600 | — | 6,322 | — | — | 133,922 |
- Employment agreement terms: originally $9,000/month plus 129 Series A Preferred shares per month; cash increased to $10,800/month effective Jan 1, 2015; extended July 1, 2025–June 30, 2026 with same general terms and up to 50% health insurance reimbursement capped at $2,500/month .
Performance Compensation
No performance metrics, targets, or payouts are disclosed for the CFO in the executive compensation tables; no bonus/PSU/options are reported for 2024–2025 . While the 2018 executive plan permits performance awards, the company states no shares have been issued under that plan to date .
Equity Ownership & Alignment
| Holder | Common Shares | % of Class | Series A Preferred Shares | % of Class | % of Voting Power |
|---|---|---|---|---|---|
| Meeta Vyas | 7,129 | <1% | 18,688 | 2.1% | 0.7% |
- Footnotes: Includes 1,072 common shares held by Connect Capital LLC over which Ms. Vyas has voting/dispositive power; excludes husband Anil Diwan’s and TheraCour holdings; excludes Armstoo Irrevocable Trust, over which Vyas disclaims beneficial ownership .
- Series A economics: Each Series A share carries nine votes and is convertible into 3.5 common shares upon a change in control .
- Outstanding awards: No unexercised options or unvested stock units reported for Ms. Vyas as of June 30, 2025 .
- Lock-up: As part of the November 2025 offering, all directors/executives entered 90-day lock-up agreements prohibiting sales, pledging, or transfers of company equity post-closing .
Employment Terms
| Term | Detail |
|---|---|
| Appointment | CFO since May 13, 2013 |
| Employment Agreement | Executed May 30, 2013; initially 3-year term; renewable annually |
| Current Extension | Effective July 1, 2025–June 30, 2026; renewable annually |
| Compensation | $9,000/month + 129 Series A/month (original); raised to $10,800/month effective Jan 1, 2015; 50% health insurance reimbursement up to $2,500/month effective July 1, 2023 and continued in 2025 extension |
| Severance | Not disclosed for CFO (Diwan’s severance terms are disclosed separately; none specific to CFO found) |
| Change-of-Control | Series A converts into 3.5 common shares upon change in control; carries nine votes per share |
| Clawback/Non-Compete | Not disclosed in cited sections |
| Other Benefits | Health insurance reimbursement per above |
Related Party Considerations
- Ms. Vyas is married to Anil Diwan (President/Chairman), a principal shareholder of TheraCour Pharma, Inc. The company discloses related party transaction policies and her compensation history in that context .
- TheraCour holds significant Series A and common shares; voting influence is concentrated; Ms. Vyas disclaims beneficial ownership of those securities .
Compensation Committee & Governance
- Committee independence: Audit, Compensation, and Nominating committees are composed of independent directors under NYSE American rules; CFO is not a committee member .
- Interlocks: No compensation committee interlocks or insider participation disclosed .
- Equity plan: 2018 Executive Equity Incentive Plan authorizes multiple award types; no shares issued under the plan to date .
- Say-on-pay: Advisory vote on named executive officer compensation on the 2025 ballot; historical approval percentages not disclosed in the cited sections .
Performance & Track Record Highlights
- Signature Brands turnaround: Returned to profitability and growth via a turnaround plan; roles included CEO, Acting COO, Vice Chairman .
- GE Appliances Range Products: Doubled operating income in under two years at a business unit with revenue exceeding $1B .
- GE IT Outsourcing: Designed strategy and initiated implementation of GE’s highly successful IT outsourcing program .
- Nonprofit leadership: As CEO of WWF-India and VP at National Audubon Society (USA), raised unrestricted funding exceeding annual requirements and instituted financial performance processes .
Fixed Compensation – Detail Table (Contract References)
| Component | Amount/Terms | Source |
|---|---|---|
| Base Cash (current) | $10,800/month (since Jan 1, 2015) | |
| Series A Preferred (historical) | 129 shares/month (per 2013 agreement; extension states “same general terms”) | |
| Health Insurance Reimbursement | Up to 50% of costs, capped at $2,500/month (effective July 1, 2023; continued in 2025 extension) |
Equity Ownership & Alignment – Additional Notes
- Shares Outstanding Base for % Calculations: 17,431,000 common and 905,717 Series A as of Oct 3, 2025 .
- Voting concentration: Series A carries nine votes per share; TheraCour’s holdings result in significant aggregate voting power; Ms. Vyas’s personal voting power is 0.7% .
- Pledging/Hedging: No pledging disclosed; 90-day lock-up temporarily restricts pledge/sale post Nov 2025 offering .
Investment Implications
- Pay-for-performance alignment: CFO compensation is predominantly fixed cash with small stock awards and no disclosed performance-linked metrics, options, or PSUs—suggesting limited short-term incentive alignment with operational/financial KPIs . The 2018 plan allows performance awards but none have been issued to date .
- Retention risk: Annual renewals and modest compensation suggest flexibility rather than heavy retention lock-ins; lack of disclosed severance or change-of-control protections for CFO reduces exit costs, but family relationship with the President/Chairman could mitigate voluntary turnover risk .
- Trading signals: Near-term insider selling pressure is reduced by the 90-day lock-up executed in connection with the Nov 2025 offering; absence of option overhang for CFO lowers mechanical sell pressures tied to expirations .
- Governance/related party: Spousal/related-party relationships, and concentrated voting power via Series A and TheraCour, are structural governance risks; investors should monitor say-on-pay outcomes and any future issuance under the executive plan for alignment improvements .